Statement of Changes in Beneficial Ownership (4)
November 23 2021 - 4:02PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lanfear Dennis M |
2. Issuer Name and Ticker or Trading Symbol
Coherus BioSciences, Inc.
[
CHRS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President & CEO |
(Last)
(First)
(Middle)
COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/17/2021 |
(Street)
REDWOOD CITY, CA 94065
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/17/2021 | | G(1) |
V
| 10000 | D | $0.00 | 436684 | I | By Trust (2) |
Common Stock | | | | | | | | 493258 | D | |
Common Stock | | | | | | | | 86965 | I | By LLC (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Gift for charitable purposes of 10,000 shares of the Company's Common Stock to a private trust. The private trust is not owned or controlled by the Reporting Person or the Reporting Person's family members and no compensation was received in return for the gift of the shares. |
(2) | These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee. |
(3) | These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lanfear Dennis M COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY, CA 94065 | X |
| President & CEO |
|
Signatures
|
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear | | 11/23/2021 |
**Signature of Reporting Person | Date |
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2024 to May 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From May 2023 to May 2024